| Outcome Measures: |
Primary: Frequency of Patients With Adverse Events (AEs), This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures., 78 weeks|Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events, 78 weeks|Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ), As significant adverse events are considered: renal Aes (SMQ 'acute renal failure'), hypersensitivity reactions ('anaphylactic reactions' and 'angioedema'), hepatic Aes ('hepatitis, non-infectious', 'hepatic failure, fibrosis, cirrhosis and other liver damage-related conditions', 'liver-related investigations, signs and symptoms', 'cholestasis and jaundice of hepatic origin'), severe cutaneous adverse reactions ('severe cutaneous adverse reaction'), pancreatitis ('acute pancreatitis', 'chronic pancreatitis'')., 78 weeks|Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events, Patients reported with cardiac and cerebrovascular events qualified for adjudication by the Clinical Event Committee (CEC), 78 weeks|Number of Patients With Abnormalities in Vital Signs, Vital sign abnormalities (any abnormalities found during PE or ECG are reported with adverse events), 78 weeks|Number of Patients With Abnormalities in Haematology: Eosinophils, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 10%., 78 weeks|Number of Patients With Abnormalities in Haematology: Haemoglobin, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 11.5 g/dL for male and as a value less than or equal to 9.5 g/dL for female patients., 78 weeks|Number of Patients With Abnormalities in Haematology: Haematocrit, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 32%., 78 weeks|Number of Patients With Abnormalities in Haematology: Red Blood Cell Count, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \* 10\^12/L., 78 weeks|Number of Patients With Abnormalities in Haematology: White Blood Cell Count, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \* 10\^9/L (decrease) or a value greater than 20.1 \* 10\^9/L (increase)., 78 weeks|Number of Patients With Abnormalities in Haematology: Platelets, For this laboratory parameter, a possibly clinically significant abnormality is defined as value less than or equal to 75 \* 10\^9/L (decrease) or a value greater than or equal to 700 \* 10\^9/L (increase)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Potassium, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 mmol/L (decrease) or a value greater than 5.8 mmol/L (increase)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 11 mg/dL for male and as a value greater than 10 mg/dL for female patients., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Amylase, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 1.5 times the upper limit of normal (ULN)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT), For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Creatinine, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 1.5 mg/dL., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Phosphate, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 0.7 mmol/L (decrease) or a value greater than 1.7 mmol/L (increase)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Calcium, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 1.8 mmol/L (decrease) or a value greater than 3 mmol/L (increase)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Sodium, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 130 mmol/L (decrease) or a value greater than 160 mmol/L (increase)., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT), For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST), For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Glucose, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 54 mg/dL., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 mg/dL., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP), For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Albumin, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 2.5 g/dL., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH), For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN., 78 weeks|Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol, For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL., 78 weeks | Secondary: Change in HbA1c From Baseline to Week 6, Baseline and week 6|Change in HbA1c From Baseline to Week 18, Baseline and week 18|Change in HbA1c From Baseline to Week 30, Baseline and week 30|Change in HbA1c From Baseline to Week 42, Baseline and week 42|Change in HbA1c From Baseline to Week 54, Baseline and week 54|Change in HbA1c From Baseline to Week 66, Baseline and week 66|Change in HbA1c From Baseline to Week 78, Baseline and week 78|Number of Patients With HbA1c<7.0% Over Time, 78 weeks|Number of Patients With HbA1c<6.5% Over Time, 78 weeks|Number of Patients With Lowered HbA1c by at Least 0.5% Over Time, 78 weeks|Change in FPG From Baseline to Week 6, Baseline and week 6|Change in FPG From Baseline to Week 18, Baseline and week 18|Change in FPG From Baseline to Week 30, Baseline and week 30|Change in FPG From Baseline to Week 42, Baseline and week 42|Change in FPG From Baseline to Week 54, Baseline and week 54|Change in FPG From Baseline to Week 66, Baseline and week 66|Change in FPG From Baseline to Week 78, Baseline and week 78
|
| Locations: |
1218.40.10003 Boehringer Ingelheim Investigational Site, Chula Vista, California, United States|1218.40.10014 Boehringer Ingelheim Investigational Site, Spring Valley, California, United States|1218.40.10001 Boehringer Ingelheim Investigational Site, Walnut Creek, California, United States|1218.40.10021 Boehringer Ingelheim Investigational Site, Northglenn, Colorado, United States|1218.40.10010 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|1218.40.10011 Boehringer Ingelheim Investigational Site, Miami, Florida, United States|1218.40.10016 Boehringer Ingelheim Investigational Site, Eugene, Oregon, United States|1218.40.10002 Boehringer Ingelheim Investigational Site, Greer, South Carolina, United States|1218.40.10004 Boehringer Ingelheim Investigational Site, Simpsonville, South Carolina, United States|1218.40.10005 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1218.40.10018 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1218.40.10007 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|1218.40.10009 Boehringer Ingelheim Investigational Site, Federal Way, Washington, United States|1218.40.54002 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1218.40.54010 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1218.40.54011 Boehringer Ingelheim Investigational Site, Mendoza, Argentina|1218.40.54015 Boehringer Ingelheim Investigational Site, Parque Velez Sarfield, Argentina|1218.40.43001 Boehringer Ingelheim Investigational Site, Graz, Austria|1218.40.43005 Boehringer Ingelheim Investigational Site, Wien, Austria|1218.40.32005 Boehringer Ingelheim Investigational Site, Brugge, Belgium|1218.40.32007 Boehringer Ingelheim Investigational Site, Brussel, Belgium|1218.40.32006 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1218.40.32004 Boehringer Ingelheim Investigational Site, Genk, Belgium|1218.40.32003 Boehringer Ingelheim Investigational Site, Gent, Belgium|1218.40.32002 Boehringer Ingelheim Investigational Site, Huy, Belgium|1218.40.32001 Boehringer Ingelheim Investigational Site, Liège, Belgium|1218.40.01005 Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|1218.40.01010 Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|1218.40.01003 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1218.40.01011 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1218.40.01006 Boehringer Ingelheim Investigational Site, Etobicoke, Ontario, Canada|1218.40.01009 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1218.40.01002 Boehringer Ingelheim Investigational Site, London, Ontario, Canada|1218.40.01012 Boehringer Ingelheim Investigational Site, Oakville, Ontario, Canada|1218.40.01008 Boehringer Ingelheim Investigational Site, Sarnia, Ontario, Canada|1218.40.20005 Boehringer Ingelheim Investigational Site, Strathroy, Ontario, Canada|1218.40.01001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1218.40.01004 Boehringer Ingelheim Investigational Site, Montague, Prince Edward Island, Canada|1218.40.01007 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|1218.40.86001 Boehringer Ingelheim Investigational Site, Beijing, China|1218.40.86002 Boehringer Ingelheim Investigational Site, Beijing, China|1218.40.86004 Boehringer Ingelheim Investigational Site, Beijing, China|1218.40.86013 Boehringer Ingelheim Investigational Site, Chengdu, China|1218.40.86009 Boehringer Ingelheim Investigational Site, Dalian, China|1218.40.86011 Boehringer Ingelheim Investigational Site, Guangzhou, China|1218.40.86014 Boehringer Ingelheim Investigational Site, Haerbin, China|1218.40.86008 Boehringer Ingelheim Investigational Site, Qingdao, China|1218.40.86015 Boehringer Ingelheim Investigational Site, Shanghai, China|1218.40.86010 Boehringer Ingelheim Investigational Site, Shenyang, China|1218.40.86007 Boehringer Ingelheim Investigational Site, Wuhan, China|1218.40.86012 Boehringer Ingelheim Investigational Site, Wuhan, China|1218.40.86006 Boehringer Ingelheim Investigational Site, Xi'An, China|1218.40.38605 Boehringer Ingelheim Investigational Site, Krapinske Toplice, Croatia|1218.40.38604 Boehringer Ingelheim Investigational Site, Slavonski Brod, Croatia|1218.40.42006 Boehringer Ingelheim Investigational Site, Breclav, Czech Republic|1218.40.42004 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1218.40.42007 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1218.40.42009 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1218.40.42008 Boehringer Ingelheim Investigational Site, Hodonin, Czech Republic|1218.40.42003 Boehringer Ingelheim Investigational Site, Olomouc, Czech Republic|1218.40.35806 Boehringer Ingelheim Investigational Site, Helsinki, Finland|1218.40.35801 Boehringer Ingelheim Investigational Site, Kuopio, Finland|1218.40.35803 Boehringer Ingelheim Investigational Site, Oulu, Finland|1218.40.35805 Boehringer Ingelheim Investigational Site, Seinäjoki, Finland|1218.40.35802 Boehringer Ingelheim Investigational Site, Turku, Finland|1218.40.49028 Boehringer Ingelheim Investigational Site, Bad Mergentheim, Germany|1218.40.49022 Boehringer Ingelheim Investigational Site, Berlin, Germany|1218.40.49024 Boehringer Ingelheim Investigational Site, Bosenheim, Germany|1218.40.49020 Boehringer Ingelheim Investigational Site, Dresden, Germany|1218.40.49101 Boehringer Ingelheim Investigational Site, Mainz, Germany|1218.40.49003 Boehringer Ingelheim Investigational Site, Neuwied, Germany|1218.40.49007 Boehringer Ingelheim Investigational Site, Nürnberg, Germany|1218.40.49014 Boehringer Ingelheim Investigational Site, Saarbrücken, Germany|1218.40.30004 Boehringer Ingelheim Investigational Site, Athens, Greece|1218.40.30007 Boehringer Ingelheim Investigational Site, Athens, Greece|1218.40.30013 Boehringer Ingelheim Investigational Site, Athens, Greece|1218.40.30003 Boehringer Ingelheim Investigational Site, Nikaia, Greece|1218.40.30011 Boehringer Ingelheim Investigational Site, Piraeus, Greece|1218.40.30006 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|1218.40.30016 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|1218.40.36003 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.40.36004 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.40.36006 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1218.40.36008 Boehringer Ingelheim Investigational Site, Debrecen, Hungary|1218.40.36005 Boehringer Ingelheim Investigational Site, Györ, Hungary|1218.40.36002 Boehringer Ingelheim Investigational Site, Szombathely, Hungary|1218.40.91010 Boehringer Ingelheim Investigational Site, Andhra Pradesh, India|1218.40.91002 Boehringer Ingelheim Investigational Site, Bangalore, India|1218.40.91005 Boehringer Ingelheim Investigational Site, Bangalore, India|1218.40.91012 Boehringer Ingelheim Investigational Site, Chennai, India|1218.40.91014 Boehringer Ingelheim Investigational Site, Chennai, India|1218.40.91009 Boehringer Ingelheim Investigational Site, Hyderabad, Andra Pradesh, India|1218.40.91006 Boehringer Ingelheim Investigational Site, Jaipur, India|1218.40.91001 Boehringer Ingelheim Investigational Site, Kerala, India|1218.40.91011 Boehringer Ingelheim Investigational Site, Maharashtra, India|1218.40.91008 Boehringer Ingelheim Investigational Site, Mangalore, India|1218.40.91007 Boehringer Ingelheim Investigational Site, Manipal, India|1218.40.91004 Boehringer Ingelheim Investigational Site, Mumbai, India|1218.40.91003 Boehringer Ingelheim Investigational Site, Nasik, India|1218.40.91013 Boehringer Ingelheim Investigational Site, Uttar Pradesh, India|1218.40.97274 Boehringer Ingelheim Investigational Site, Afula, Israel|1218.40.97273 Boehringer Ingelheim Investigational Site, Haifa, Israel|1218.40.97275 Boehringer Ingelheim Investigational Site, Holon, Israel|1218.40.97271 Boehringer Ingelheim Investigational Site, Jerusalem, Israel|1218.40.97272 Boehringer Ingelheim Investigational Site, Nahariya, Israel|1218.40.97276 Boehringer Ingelheim Investigational Site, Safed, Israel|1218.40.97278 Boehringer Ingelheim Investigational Site, Tel Aviv, Israel|1218.40.39008 Boehringer Ingelheim Investigational Site, Genova, Italy|1218.40.39002 Boehringer Ingelheim Investigational Site, Milano, Italy|1218.40.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|1218.40.39006 Boehringer Ingelheim Investigational Site, Roma, Italy|1218.40.81001 Boehringer Ingelheim Investigational Site, Amagasaki, Hyogo, Japan|1218.40.81005 Boehringer Ingelheim Investigational Site, Koganei, Tokyo, Japan|1218.40.81002 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1218.40.81004 Boehringer Ingelheim Investigational Site, Shinjyuku-ku,Tokyo, Japan|1218.40.81003 Boehringer Ingelheim Investigational Site, Suita, Osaka,, Japan|1218.40.82002 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of|1218.40.82011 Boehringer Ingelheim Investigational Site, Daegu, Korea, Republic of|1218.40.82008 Boehringer Ingelheim Investigational Site, Incheon, Korea, Republic of|1218.40.82010 Boehringer Ingelheim Investigational Site, Jeonju, Korea, Republic of|1218.40.82004 Boehringer Ingelheim Investigational Site, Pusan, Korea, Republic of|1218.40.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.40.82005 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.40.82006 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.40.82007 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.40.82009 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|1218.40.82003 Boehringer Ingelheim Investigational Site, Suwon, Korea, Republic of|1218.40.60003 Boehringer Ingelheim Investigational Site, Kelantan, Malaysia|1218.40.60001 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia|1218.40.60002 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia|1218.40.60007 Boehringer Ingelheim Investigational Site, Penang, Malaysia|1218.40.60004 Boehringer Ingelheim Investigational Site, Perak, Malaysia|1218.40.60005 Boehringer Ingelheim Investigational Site, Perak, Malaysia|1218.40.52007 Boehringer Ingelheim Investigational Site, Aguascalientes, Ags., Mexico|1218.40.52010 Boehringer Ingelheim Investigational Site, Col.Americana, Guadalajara, Jalisco, Mexico|1218.40.52008 Boehringer Ingelheim Investigational Site, Colonia Tlalpan, mexico, Mexico|1218.40.52006 Boehringer Ingelheim Investigational Site, Faccionamiento Lomas de Campestre,AGUASCAL, Mexico|1218.40.52009 Boehringer Ingelheim Investigational Site, León, Mexico|1218.40.52001 Boehringer Ingelheim Investigational Site, Monterrey N.L., Mexico|1218.40.52003 Boehringer Ingelheim Investigational Site, Monterrey, Mexico|1218.40.52002 Boehringer Ingelheim Investigational Site, México, Mexico|1218.40.52004 Boehringer Ingelheim Investigational Site, México, Mexico|1218.40.52005 Boehringer Ingelheim Investigational Site, México, Mexico|1218.40.31006 Boehringer Ingelheim Investigational Site, Deurne, Netherlands|1218.40.31001 Boehringer Ingelheim Investigational Site, Ewijk, Netherlands|1218.40.31010 Boehringer Ingelheim Investigational Site, Losser, Netherlands|1218.40.31008 Boehringer Ingelheim Investigational Site, Roelofarendsveen, Netherlands|1218.40.31002 Boehringer Ingelheim Investigational Site, Wildervank, Netherlands|1218.40.64004 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand|1218.40.64003 Boehringer Ingelheim Investigational Site, Dunedin, New Zealand|1218.40.64002 Boehringer Ingelheim Investigational Site, Otahuhu, New Zealand|1218.40.64001 Boehringer Ingelheim Investigational Site, Tauranga, New Zealand|1218.40.64005 Boehringer Ingelheim Investigational Site, Wellington, New Zealand|1218.40.63003 Boehringer Ingelheim Investigational Site, Greenhills, San Juan, Philippines|1218.40.63005 Boehringer Ingelheim Investigational Site, Manila, Philippines|1218.40.63002 Boehringer Ingelheim Investigational Site, Marikina, Philippines|1218.40.63001 Boehringer Ingelheim Investigational Site, Pasig, Philippines|1218.40.63004 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|1218.40.48603 Boehringer Ingelheim Investigational Site, Lublin, Poland|1218.40.48601 Boehringer Ingelheim Investigational Site, Warsaw, Poland|1218.40.48604 Boehringer Ingelheim Investigational Site, Zabrze, Poland|1218.40.40504 Boehringer Ingelheim Investigational Site, Alba Iulia, Romania|1218.40.40604 Boehringer Ingelheim Investigational Site, Brasov, Romania|1218.40.40501 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1218.40.40502 Boehringer Ingelheim Investigational Site, Bucharest, Romania|1218.40.40603 Boehringer Ingelheim Investigational Site, Galati, Romania|1218.40.40503 Boehringer Ingelheim Investigational Site, Sibiu, Romania|1218.40.40505 Boehringer Ingelheim Investigational Site, Targu-Mures, Romania|1218.40.70014 Boehringer Ingelheim Investigational Site, Arkhangelsk, Russian Federation|1218.40.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1218.40.70002 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1218.40.70003 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1218.40.70012 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1218.40.70005 Boehringer Ingelheim Investigational Site, Novosibirsk, Russian Federation|1218.40.70006 Boehringer Ingelheim Investigational Site, Perm, Russian Federation|1218.40.70013 Boehringer Ingelheim Investigational Site, Rostov-on-Don, Russian Federation|1218.40.70016 Boehringer Ingelheim Investigational Site, Samara, Russian Federation|1218.40.70015 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1218.40.70004 Boehringer Ingelheim Investigational Site, Tomsk, Russian Federation|1218.40.42103 Boehringer Ingelheim Investigational Site, Banska Bystrica, Slovakia|1218.40.42102 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.40.42104 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.40.42105 Boehringer Ingelheim Investigational Site, Bratislava, Slovakia|1218.40.42101 Boehringer Ingelheim Investigational Site, Nove Mesto, Slovakia|1218.40.42106 Boehringer Ingelheim Investigational Site, Samorin, Slovakia|1218.40.34002 Boehringer Ingelheim Investigational Site, Badalona, Spain|1218.40.34011 Boehringer Ingelheim Investigational Site, Badia del Vallés, Spain|1218.40.34012 Boehringer Ingelheim Investigational Site, Borges del Camp, Spain|1218.40.34013 Boehringer Ingelheim Investigational Site, Centelles, Spain|1218.40.34007 Boehringer Ingelheim Investigational Site, Granada, Spain|1218.40.34008 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona), Spain|1218.40.34009 Boehringer Ingelheim Investigational Site, L'Hospitalet de Llobregat (Barcelona), Spain|1218.40.34004 Boehringer Ingelheim Investigational Site, Madrid, Spain|1218.40.34006 Boehringer Ingelheim Investigational Site, Madrid, Spain|1218.40.34010 Boehringer Ingelheim Investigational Site, Sant Adrià del Besós (Barcelona), Spain|1218.40.34005 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1218.40.34014 Boehringer Ingelheim Investigational Site, Vic (Barcelona), Spain|1218.40.46013 Boehringer Ingelheim Investigational Site, Härnösand, Sweden|1218.40.46001 Boehringer Ingelheim Investigational Site, Malmö, Sweden|1218.40.46012 Boehringer Ingelheim Investigational Site, Uddevalla, Sweden|1218.40.46004 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1218.40.88605 Boehringer Ingelheim Investigational Site, ChangHua, Taiwan|1218.40.88604 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|1218.40.88606 Boehringer Ingelheim Investigational Site, Tainan, Taiwan|1218.40.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1218.40.88602 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1218.40.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1218.40.88607 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|1218.40.88608 Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan|1218.40.66001 Boehringer Ingelheim Investigational Site, Bangkok, Thailand|1218.40.66002 Boehringer Ingelheim Investigational Site, Khon Kaen, Thailand|1218.40.38011 Boehringer Ingelheim Investigational Site, Dnepropetrovsk, Ukraine|1218.40.38002 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1218.40.38004 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1218.40.38010 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|1218.40.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.40.38005 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.40.38008 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.40.38009 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.40.38012 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1218.40.38003 Boehringer Ingelheim Investigational Site, Lvov, Ukraine|1218.40.38006 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|1218.40.38007 Boehringer Ingelheim Investigational Site, Zaporizhzhya, Ukraine|1218.40.44005 Boehringer Ingelheim Investigational Site, Ashford, United Kingdom|1218.40.44004 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow, United Kingdom|1218.40.44001 Boehringer Ingelheim Investigational Site, Bath, United Kingdom|1218.40.44003 Boehringer Ingelheim Investigational Site, Burbage, United Kingdom|1218.40.44010 Boehringer Ingelheim Investigational Site, Bury St Edmonds, United Kingdom|1218.40.44009 Boehringer Ingelheim Investigational Site, Cardiff, United Kingdom|1218.40.44002 Boehringer Ingelheim Investigational Site, Penarth, United Kingdom|1218.40.44006 Boehringer Ingelheim Investigational Site, Reading, United Kingdom|1218.40.44007 Boehringer Ingelheim Investigational Site, Waterloo, Liverpool, United Kingdom
|
